Constitutive activation of c‐Met is correlated with c‐Met overexpression and dependent on cell–matrix adhesion in lung adenocarcinoma cell lines

In this study we explored the mechanisms of constitutive activation of c‐Met in lung adenocarcinoma cell lines. First, we examined levels of c‐Met and phospho‐c‐Met (Y1234/Y1235) in a panel of lung adenocarcinoma cell lines by Western blot analysis. c‐Met expression was found in 12 of 14 cell lines and an overall correlation between the expressions of c‐Met and phospho‐c‐Met was noted. c‐Met was constitutively activated particularly at high levels in five cell lines (PC3, LC‐2/ad, L27, H1648, and H2009). c‐Met amplification was identified in L27 and H1648 by single nucleotide polymorphism array analysis, but no mutations were identified in the Sema domain or in any part of the cytoplasmic domain of c‐Met. Experiments with neutralizing anti‐hepatocyte growth factor (HGF) antibody, scatter assay using Madin–Darby canine kidney cells, and Western blotting on conditioned media of the cell lines revealed that the constitutive phosphorylation of c‐Met was largely ligand‐independent. The inhibition of cell–matrix adhesion induced the dephosphorylation of c‐Met in the five cell lines tested. This was accompanied by downregulation of c‐Met in three of the five cell lines. In contrast, the inhibition of cell–cell adhesion by neutralizing E‐cadherin antibody had a minimal effect on the expression and phosphorylation of c‐Met. These results reveal three features of the constitutive activation of c‐Met in our panel of lung adenocarcinoma cell lines: (i) it correlates with c‐Met overexpression, either with or without gene amplification; (ii) it is largely ligand‐independent; and (iii) it depends on cell–matrix adhesion. (Cancer Sci 2008; 99: 14–22)

[1]  Yusuke Nakamura,et al.  c‐Met activation in lung adenocarcinoma tissues: An immunohistochemical analysis , 2007, Cancer science.

[2]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[3]  S. Ishikawa,et al.  Hypoxia increases the motility of lung adenocarcinoma cell line A549 via activation of the epidermal growth factor receptor pathway , 2007, Cancer science.

[4]  W. Pao,et al.  Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[5]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[6]  Gayatry Mohapatra,et al.  Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[7]  S. Ishikawa,et al.  Differential expression of S100A2 and S100A4 in lung adenocarcinomas: Clinicopathological significance, relationship to p53 and identification of their target genes , 2005, Cancer science.

[8]  S. Hirohashi,et al.  Genetic Classification of Lung Adenocarcinoma Based on Array-Based Comparative Genomic Hybridization Analysis: Its Association with Clinicopathologic Features , 2005, Clinical Cancer Research.

[9]  Hiroyuki Aburatani,et al.  Allelic dosage analysis with genotyping microarrays. , 2005, Biochemical and biophysical research communications.

[10]  J. Christensen,et al.  c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. , 2005, Cancer letters.

[11]  Ravi Salgia,et al.  Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. , 2005, Cancer research.

[12]  Wenjun Guo,et al.  Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.

[13]  K. Miyazawa,et al.  Activation of c‐Met (hepatocyte growth factor receptor) in human gastric cancer tissue , 2004, Cancer science.

[14]  R. Kramer,et al.  Adhesion-mediated squamous cell carcinoma survival through ligand-independent activation of epidermal growth factor receptor. , 2004, The American journal of pathology.

[15]  H. Kawamata,et al.  Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R. , 2004, The American journal of pathology.

[16]  L. Schmidt,et al.  The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants , 2004, Oncogene.

[17]  Douglas R Lowy,et al.  E‐cadherin‐mediated adhesion inhibits ligand‐dependent activation of diverse receptor tyrosine kinases , 2004, The EMBO journal.

[18]  R. Haba,et al.  The tumour–stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients , 2004, British Journal of Cancer.

[19]  J. Christensen,et al.  c-Met: Structure, functions and potential for therapeutic inhibition , 2003, Cancer and Metastasis Reviews.

[20]  R. Salgia,et al.  c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. , 2003, Cancer research.

[21]  S. Hirohashi,et al.  Cell adhesion system and human cancer morphogenesis , 2003, Cancer science.

[22]  Miyuki Saito,et al.  Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas. , 2002, The American journal of pathology.

[23]  L. Ferrell,et al.  Activation of the Met Receptor by Cell Attachment Induces and Sustains Hepatocellular Carcinomas in Transgenic Mice , 2001, The Journal of cell biology.

[24]  P. Leung,et al.  Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis? , 2001, Oncogene.

[25]  J. Coebergh,et al.  Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. , 2001, Lung cancer.

[26]  M. Tsao,et al.  Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. , 1998, Lung cancer.

[27]  H. Asamura,et al.  Implications of staging in lung cancer. , 1997, Chest.

[28]  S. Ōmura,et al.  Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway , 1997, Molecular and cellular biology.

[29]  T. Yamamoto,et al.  Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers. , 1996, Oncology.

[30]  J. Bishop,et al.  Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Hirohashi,et al.  Human Lung Cancer Cell Line Producing Hepatocyte Growth Factor/Scatter Factor , 1992, Japanese journal of cancer research : Gann.

[32]  H. Tsubouchi,et al.  The presence of scatter factor in patients with metastatic spread to the pleura. , 1992, British Journal of Cancer.

[33]  G. Michalopoulos,et al.  Hepatocyte growth factor , 1992, Hepatology.

[34]  L. Naldini,et al.  Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. , 1991, The Journal of biological chemistry.

[35]  S. Hirohashi,et al.  Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas. , 1989, Cancer research.

[36]  W. Jiang,et al.  Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. , 2005, Critical reviews in oncology/hematology.

[37]  R. Salgia,et al.  Role of receptor tyrosine kinases in lung cancer. , 2003, Methods in molecular medicine.

[38]  B. Elliott,et al.  Constitutive activation of met kinase in non‐small‐cell lung carcinomas correlates with anchorage‐independent cell survival , 2002, Journal of cellular biochemistry.

[39]  W. Severs,et al.  Subject Index, Vol. 53, 1996 , 1996 .